Targeting of HBP1/TIMP3 axis as a novel strategy against breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Breast cancer mortality is primarily driven by malignant proliferation and metastasis.
• The tumor suppressor high mobility group (HMG) box-containing protein 1 (HBP1) is frequently deleted or mutated in tumors.
• Understanding HBP1's role in breast cancer is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the function of HBP1 in suppressing breast cancer.
• To elucidate the molecular mechanisms underlying HBP1's tumor-suppressive activity.
• To explore the therapeutic implications of the HBP1/TIMP3 axis in breast cancer treatment.

Main Methods:

• Analysis of HBP1's effect on the tissue inhibitors of metalloproteinases 3 (TIMP3) promoter activity.
• Quantification of TIMP3, phosphatase and tensin homolog (PTEN), and matrix metalloproteinase (MMP2/9) protein and mRNA levels.
• Assessment of the HBP1/TIMP3 axis's role in breast cancer progression and response to therapy.

Main Results:

• HBP1 enhances TIMP3 promoter activity, increasing TIMP3 protein and mRNA levels.
• TIMP3 upregulates PTEN by inhibiting its degradation and downregulates MMP2/9.
• HBP1 deletion disrupts the HBP1/TIMP3 axis, promoting breast cancer occurrence and progression.

Conclusions:

• The HBP1/TIMP3 axis is a critical suppressor of breast cancer tumorigenesis.
• HBP1 deletion contributes to malignant progression and therapeutic resistance in breast cancer.
• Targeting the HBP1/TIMP3 axis offers new therapeutic strategies and improves prognosis for breast cancer patients.